Immunotherapies have transformed cancer treatment, but considerable challenges remain. At Mural Oncology, we are using our advanced protein engineering capabilities to broaden the potential and reach of cytokine-based immunotherapies for people with cancer. Our lead candidate, nemvaleukin, is an investigational, engineered interleukin-2 (IL-2) cytokine designed to capture and expand the therapeutic benefits of high-dose native IL-2 while mitigating the cytokine’s hallmark toxicities. It is currently in two potentially registrational trials reading out next year. Discover our pipeline and learn about the clinical trials evaluating nemvaleukin: https://bit.ly/49hUu3c #biotechnology #oncology #drugdevelopment
Mural Oncology
Biotechnology Research
Waltham, Massachusetts 4,374 followers
Leveraging our protein engineering platform to improve cytokine-based immunotherapies for the treatment of #cancer
About us
We know that drug development is both an art and a science. The work we do is incredibly technical, intentional, and specific, but there is an art to it - because we must leave room for creativity, innovation and spontaneity. Murals are paintings that transform overlooked or unused spaces - creating something impactful and meaningful. There remains many overlooked opportunities in cancer drug development. This is what inspires us. Our mission is simple, to create novel immunotherapies that can change patients’ lives so they can get back to what matters most - living. Mural Oncology is leveraging its industry-leading protein engineering platform to revolutionize cytokine-based immunotherapies for the treatment of cancer. Immunotherapies have been transformative for some people living with cancer, but unfortunately many patients still do not benefit - either because they are ineligible for treatment or they do not respond well to current therapies. We leverage our expertise in cytokine biology, immune cell modulation and our protein engineering capabilities to develop first and novel immunotherapies. Our goal is to deliver meaningful, clinical benefit across a wide range of cancers, including tumor types where immunotherapies have previously not been effective. Mural Oncology is developing a portfolio of programs to broaden the potential and reach of cytokine-based immunotherapies for the treatment of cancers. (NASDAQ: MURA)
- Website
-
http://www.muraloncology.com
External link for Mural Oncology
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Waltham, Massachusetts
- Type
- Public Company
- Founded
- 2023
- Specialties
- immuno-oncology, cytokine biology, cancer, drug discovery, nemvaleukin alfa, interleukin-18, interleukin-12, immune cell modulation, protein engineering, cytokine therapies, immunotherapy, nemvaleukin, platinum-resistant ovarian cancer, ovarian cancer, proinflammatory cytokines, and mucosal melanoma
Locations
-
Primary
Get directions
852 Winter St
Waltham, Massachusetts 02451, US
Employees at Mural Oncology
Updates
-
Thanks to Longwood Healthcare Leaders for having us at the Spring MIT Conference. Our CEO, Caroline J Loew, PhD, joined a panel discussion with Robert Beardsley, Kinnari Patel, PharmD, MBA, and Brian Goff to discuss how to successfully advance late-stage assets. Caroline’s number one focus for a later-stage company: having the right people in the right roles. Since joining Mural, she has added team members with significant late-stage oncology expertise at all levels of the organization. #LongwoodHealthcareLeaders #oncology #biotechnology
Great discussion on advancing late-stage assets with Agios Pharmaceuticals CEO Brian Goff, Mural Oncology CEO Caroline J Loew, PhD, Rocket Pharmaceuticals COO Kinnari Patel, PharmD, MBA and Galera Therapeutics, Inc. COO Robert Beardsley
-
-
Mural CEO Caroline J Loew, PhD will join Kinnari Patel, PharmD, MBA, Brian Goff, and Robert Beardsley tomorrow at the Longwood Healthcare Leaders Spring MIT conference for a panel discussion about advancing late-stage assets. Co-hosted by MIT Institute Professors Phillip Sharp and Robert Langer, this year’s event brings together leading executives, researchers, and investors for a two-day forum focused on the most important topics affecting the biopharma industry. Learn more: https://lnkd.in/exxKDits #biotechnology #leadership
-
-
Gabrielle Masson at Fierce Biotech spoke with industry leaders at the American Society of Clinical Oncology (ASCO) conference to get their perspectives on #ASCO2024 and the current biotech market. See what Mural CEO Caroline J Loew, PhD, had to say about how investors are being more discriminating, prioritizing late-stage assets and proven science: https://lnkd.in/eXCjkJPW #innovation #oncology
-
We're looking forward to attending the 14th annual East Coast IDEAS investor conference next Thursday. Read here for more information about the conference and where to access the webcast: https://bit.ly/4c7Cj15 Three Part Advisors, LLC #ideasconference #biotechnology
-
-
Did you catch our poster presentation at the American Society of Clinical Oncology (ASCO) annual meeting? See the data that were presented on our lead candidate, nemvaleukin alfa, and view all of our recent publications: https://bit.ly/3KrYlzM #biotechnology #drugdevelopment #ASCO24 #innovation
-
-
Thanks to the Cytokine-Based Drug Development Summit for having us! Our Head of Medical Affairs, Zhonghong Eric Guan, MD, PhD, shared how we take a fit-for-purpose approach to engineered cytokines across our pipeline. He shared an overview of our late-stage candidate, nemvaleukin, which is designed to mitigate toxicities linked to native IL-2 through a highly differentiated approach with the potential to be best in class. He also spotlighted our unique protein engineering approach with our IL-18 and IL-12 programs, which we intend to nominate candidates for later this year. #biotechnology #innovation #drugdevelopment
-
-
Did you know that cutaneous melanoma is the most aggressive form of melanoma? An estimated 90% of cases are caused by excessive UV exposure. Learn more about the cancer, including the signs and symptoms, or ABCDE’s: https://bit.ly/4ajYFuV #MelanomaAwarenessMonth24
-
We’re looking forward to the American Society of Clinical Oncology (ASCO) annual meeting. Sarina Piha-Paul, MD will give a poster presentation on the ARTISTRY-3 clinical trial evaluating the effects of less frequent IV dosing (LFIV) of our lead candidate, nemvaleukin alfa. It is an investigational, engineered interleukin-2 (IL-2) cytokine designed to capture and expand the therapeutic benefits of high-dose native IL-2 while mitigating the cytokine’s hallmark toxicities: Learn more: https://bit.ly/4bPBl9B #biotechnology #oncology #ASCO24
-
-
What is mucosal melanoma? It is not related to UV exposure and there are no obvious identified risk factors. In recognition of #MelanomaAwarenessMonth, visit the Melanoma Research Foundation to learn more about the signs and symptoms of this rare form of melanoma: https://bit.ly/3UTAyik #MelanomaAwarenessMonth224